Retatrutide posts strong results in knee osteoarthritis

Eli Lilly reported in December 2025 that its experimental drug retatrutide led to 26.6% placebo-adjusted weight loss at 68 weeks in the Phase 3 TRIUMPH-4 trial, which enrolled people with obesity or overweight who also had knee osteoarthritis ^[1]. Analysts at BMO Capital Markets said the result helps "solidify retatrutide's profile as an even higher efficacy next generation GLP-1+ asset" ^[1].

Retatrutide is not the same kind of drug as Lilly's other weight-loss products. It is a "triple-G" agonist, meaning it targets three different hormone receptors at once, and William Blair analyst Andy Hsieh has said Lilly considers it part of "a different drug category" compared with the company's GLP-1/GIP drug Zepbound and its small-molecule pill Foundayo ^[1]. In a separate Phase 3 study called TRIUMPH-1, announced in May 2025, retatrutide produced 28.3% weight loss over 80 weeks in people with obesity but without diabetes, results Lilly compared to what bariatric surgery can achieve ^[1].

The TRIUMPH-4 data also came with a caution. Lilly reported a side effect called dysesthesia — a neurological problem involving unpleasant or painful sensations — in more than one-fifth of patients taking the 20-milligram dose of retatrutide in that trial ^[1]. Dysesthesia also showed up in the TRIUMPH-1 study, with the rate increasing as the dose went up ^[1]. Because of this, analysts expect ongoing debate about whether retatrutide's extra weight-loss power is worth the tolerability tradeoff ^[1].

Why it matters for patients

For people managing both excess weight and joint pain from osteoarthritis, a drug that produces substantial weight loss could matter because carrying less weight reduces stress on joints like the knee. The 26.6% placebo-adjusted result in TRIUMPH-4 is among the largest weight-loss figures reported so far for any GLP-1-related drug in a real-world condition like osteoarthritis, according to the source reporting these figures ^[1].

At the same time, the dysesthesia signal is a reminder that higher potency can come with new or different side effects that were less prominent in earlier, smaller studies. More than one in five patients on the highest studied dose experienced this nerve-related symptom in TRIUMPH-4, and rates rose with dose in the other major trial as well ^[1]. This is not yet an approved medicine, and it is not yet known how regulators or doctors will weigh this side effect against the drug's weight-loss benefits once more complete safety data are available.

Patients should also know that retatrutide is still investigational. It has not been approved by the Food and Drug Administration, and none of the specific trials mentioned here have led to a marketing decision as of the reporting in this source ^[1].

What happens next

More detailed results and further scientific scrutiny are expected as Lilly continues its retatrutide development program alongside its already-marketed drugs Zepbound and Foundayo ^[1]. Analysts have noted that retatrutide will likely be compared against competing next-generation obesity drugs from other companies, including Novo Nordisk's CagriSema, Boehringer Ingelheim and Zealand Pharma's survodutide, and Roche's CT-388, all of which are also working through the drug development process ^[1]. The source does not specify a date for an FDA filing or approval decision for retatrutide, so a timeline for when — or whether — the drug might reach pharmacies is not yet known.